This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
Save the dateMarch 17–19, 2025 | Milan, Italy

Oscar Perez
CSO at Ferrer


Throughout his 24-year biopharma career Oscar Pérez Albet has been devoted to leading diverse high-performing teams by successfully managing culture and organization transformation at global and local level in top-notch public biopharmas, Amgen and Celgene.

Six years ago, Oscar took a Chief Officer seat at the Ferrer executive management team to devise and execute a business turnaround strategy which primarily lies on gaining focus and efficiency, that is, prioritized medical conditions and talent attraction and development. Most recently, because of his successful leadership of the Business Development activity and its respective teams, Oscar has been appointed to Chief Scientific and Business Development Officer, being responsible for the direction, development, and implementation of Ferrer's scientific strategy.

Day to day, Oscar and his leadership are dutiful to demonstrating that being a company socially responsible and profitable all at once is indeed possible.

On top of his deep knowledge and know-how on defining and implementing a global strategy as well as managing markets, Oscar is an excellent communicator and a seasoned deal negotiator and currently oversees R&D and business development and alliance management global groups at Ferrer.

He has a passion for teaching and is a highly committed professor and frequent mentor of budding innovators and entrepreneurs and serves as a key academic collaborator at different business schools. In addition, Oscar performs as a frequent speaker at global healthcare forums.

As an experienced and knowledgeable professional, Oscar has advised successful biotech firms throughout their overseas roll-out plans, and cumulates a meaningful track record in Oncology, Hematology, Nephrology, Dermatology, Rheumatology, Cardio-metabolism, Neurology, and Rare Diseases like Pulmonary Hypertension and Multiple Myeloma, among others.

Agenda Sessions

  • Startup spotlight pitch competition